Notably, integrating TOP2A inhibitors into platinum-based regimens has shown promise in enhancing chemosensitivity and mitigating resistance in recurrent OC, while TOP2A quantification in both tumor and stromal compartments serves as a prognostic biomarker for treatment outcomes (49). The gene discussed is TOP2A; the disease is neoplasm.